Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Systematix Group Pharma & Healthcare Conference 2024
35 slides from Jubilant Pharmova's conference presentation, Mar 5, 2024
Slide 1: Intimation of Investors/Analysts Meeting
March 5, 2024 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Dear Sirs, Sub.: Intimation of Investors/ Analysts Mee
Slide 2: Covering letter to stock exchanges
The above mentioned document will be simultaneously posted on the Company's website at www.jubilantpharmova.com. We also enclose herewith the presentation to be discussed during the meetings. This is for your information and record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Nares
Slide 3: Investor Presentation March 2024
Investor Presentation March, 2024
Slide 4: Uniquely positioned to create sustained Shareholder Value
Jubilant Pharmova is uniquely positioned to create sustained Shareholder Value An integrated global Over 5,500 people globally, 6 manufacturing facilities catering Strong position in Radiopharmaceuticals, pharmaceuticals and contract including over 2,100 in to regulated markets including USA, Allerg
Slide 5: Business Structure
Business Structure Jubilant Pharmova Limited CDMO Sterile Allergy Proprietary Radiopharma CRDMO Generics Injectables Immunotherapy Novel Drugs Radiopharmaceuticals Radiopharmacies Drug Discovery CDMO - API Services 2
Slide 6: 9M'FY24 – Segment Wise Revenue Split
9M’FY24 – Segment Wise Revenue Split Allergy Immunotherapy 10% Radiopharma Generics 44% 12% CDMO Sterile Injectables 17% CRDMO 17% 3
Slide 7: Business Snapshot
Business Snapshot • #3 radiopharmaceutical • #2 player in the US allergenic • Leading contract manufacturer • Manufacturing facilities at manufacturer in the US extract market for Sterile Injectables Roorkee, India and Salisbury, US • Sole supplier of venom in the • Differentiated technologies, viz.
Slide 8: High-Quality, World-Class Manufacturing Footprint and Operational Facilities
High-Quality, World-Class Manufacturing Footprint and Operational Facilities Biosys Gr. Noida Facility Spokane, Washington, USA Contract manufacturing of Sterile injectable and Allergy therapy Roorkee, Uttarakhand Generics manufacturing Noida Montreal, Canada Corporate Office Contract Manufact
Slide 9: Financial Highlights Q3 & 9M'FY24
Financial Highlights Q3 & 9M’FY24 Jubilant Pharmova Limited
Slide 10: Financial Results Overview Q3'FY24 - Consolidated
Financial Results Overview Q3’FY24 Figures in Rs Cr. - Consolidated Particulars Q3’FY23 Q2’FY24 Q3’FY24 Total Income 1,562 1,690 1,713 EBITDA 155 252 254 EBITDA Margin (%) 9.9% 14.9% 14.8% Share of profit / (loss) of associates (2) 9 13 PBT 9 98 101 PBT Margin 0.6% 5.8% 5.9% PAT (16) 62 66 • Total I
Slide 11: Financial Results Overview 9M'FY24 - Consolidated
Financial Results Overview 9M’FY24 Figures in Rs Cr. - Consolidated Particulars 9M’FY23 9M’FY24 Total Income 4,638 4,999 EBITDA 591 684 EBITDA Margin (%) 12.7% 13.7% Share of profit / (loss) of associates (5) 21 Exceptional Items on bonds refinancing (57) 0 PBT 114 224 PBT Margin 2.5% 4.5% PAT 36 13
Slide 12: Debt 9M'FY24 - Consolidated
Debt 9M’FY24 Figures in Rs Cr. - Consolidated Particulars Mar 31, 2023 Sep 30, 2023 Dec 31, 2023 Long Term* 3,152 3,202 3,211 Short Term 258 218 208 Total Gross Debt 3,410 3,420 3,419 Total Gross Debt (On constant currency ) 3,410 3,388 3,381 * Excluding Debt Initiation Cost Exchange Rate : 1 USD =
Slide 13: Financial Highlights Radiopharmaceuticals
Financial Highlights Radiopharmaceuticals Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 213 251 241 657 696 % of Company Revenue 14% 15% 14% 14% 14% EBITDA 109 132 126 365 352 EBITDA Margin (%) 51% 53% 52% 56% 51% • Q3’FY24 & 9M’FY24 revenue grew YoY on the back of ne
Slide 14: Radiopharmaceuticals Key Priorities
Key Priorities Radiopharmaceuticals • Maintain leadership position in stable high margin core portfolio in North America, e.g., lung functional imaging and thyroid targeted radiotherapeutics • Innovation leader in PET cardiac imaging through proprietary RUBY-FILL (best in class cardiac imaging produ
Slide 15: Financial Highlights Radiopharmacies
Financial Highlights Radiopharmacies Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 400 490 511 1,206 1,488 % of Company Revenue 26% 29% 30% 26% 30% EBITDA (45) 6 10 (82) 18 EBITDA Margin (%) (11%) 1% 2% (7%) 1% • Q3’FY24 & 9M’FY24 revenue grew YoY on the back of incre
Slide 16: Radiopharmacies Key Priorities
Key Priorities Radiopharmacies • Accelerate sales of high growth new products, e.g., Ga-PSMA, and to further gain market share in existing SPECT products • Maintain current momentum of strong growth in 3rd party sales • Leverage existing cyclotrons to capture share of PET product growth • Additional
Slide 17: Value Creation by Investment in PET radiopharmacy business
Value Creation by Investment in PET radiopharmacy business Validation of our Investment thesis in PET radiopharmacy Business • JPL, Company’s wholly owned subsidiary invested USD 25 Mn. in 139.43 Nov’2020 in Sofie Biosciences Inc. (‘Sofie’). JPL holds 25.8% stake 25.8 Milestone based in Future • Sof
Slide 18: Financial Highlights Radiopharma
Financial Highlights Radiopharma Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 613 741 752 1,863 2,184 % of Company Revenue 39% 44% 45% 40% 44% EBITDA 64 138 161 283 395 EBITDA Margin (%) 10% 19% 21% 15% 18% • Q3’FY24 & 9M’FY24 EBITDA includes ‘EBITDA share from Sofie
Slide 19: Financial Highlights Allergy Immunotherapy
Financial Highlights Allergy Immunotherapy Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 147 179 161 433 491 % of Company Revenue 9% 11% 10% 9% 10% EBITDA 53 86 62 150 198 EBITDA Margin (%) 36% 48% 38% 35% 40% • Q3’FY24 & 9M’FY24 revenue & EBITDA grew YoY on the back
Slide 20: Allergy Immunotherapy Key Priorities
Key Priorities Allergy Immunotherapy • #2 player in US Sub-Cutaneous Immunotherapy market (Venom and Non-Venom) of >$200M. High barriers to entry as products are branded biologicals with regulatory approvals grandfathered in • Further strengthen the prescriber base for Venom immunotherapy in the US
Slide 21: Financial Highlights CDMO Sterile Injectables
Financial Highlights CDMO Sterile Injectables Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 272 301 303 834 858 % of Company Revenue 18% 18% 18% 18% 17% EBITDA 56 56 37 259 134 EBITDA Margin (%) 21% 19% 12% 31% 16% Adjusted EBITDA 173 134 • Q3’FY24 and 9M’FY24 revenue
Slide 22: CDMO Sterile Injectables Key Priorities
Key Priorities CDMO Sterile Injectables • Global Fill and Finish Sterile Injectable markets of USD 13Bn, with double digit growth rate projected over next 5 years • Focus is on-time and at-cost execution of USD 370Mn capacity expansion in Spokane and Montreal, to double the CMO capacity over next 5+
Slide 23: Financial Highlights Generics
Financial Highlights Generics Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 223 172 199 563 573 % of Company Revenue 14% 10% 12% 12% 12% EBITDA (36) (50) (31) (191) (102) EBITDA Margin (%) (16%) (29%) (15%) (34%) (18%) Adjusted EBITDA (211) (65) • Q3’FY23 Adjusted Rev
Slide 24: Generics Key Priorities
Key Priorities Generics • Continue quality improvement initiatives and engagement with the US FDA for resolution of Import Alert at the Roorkee facility • Salisbury site is compliant with US FDA. Roorkee site is compliant with other key non-US markets, e.g., MHRA, Japan, South Africa, Canada • Under
Slide 25: Financial Highlights Drug Discovery Services
Financial Highlights Drug Discovery Services Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 123 115 114 391 332 % of Company Revenue 8% 7% 7% 8% 7% EBITDA 37 26 30 130 78 EBITDA Margin (%) 30% 22% 27% 33% 23% • Industry headwinds in Biotech Industry is on account of lo
Slide 26: Drug Discovery Services Key Priorities
Key Priorities Drug Discovery Services • Leverage state of the art infrastructure and differentiated technical know-how, e.g., Integrated Drug Discovery, DMPK to drive new customer acquisitions in drug discovery • Continue to invest in capabilities for improving productivity, speeding up time to mar
Slide 27: Financial Highlights CDMO - API
Financial Highlights CDMO - API Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 168 165 138 500 480 % of Company Revenue 11% 10% 8% 11% 10% EBITDA 2 15 11 23 39 EBITDA Margin (%) 1% 9% 8% 5% 8% • Q3’FY24 and 9M’FY24 revenue decreased YoY mainly due to pricing pressure i
Slide 28: CDMO - API Key Priorities
Key Priorities CDMO - API • In March 2023, the API plant at Nanjangud saw reversal of OAI status to compliant VAI status from USFDA, driven by Quality Improvement Initiatives at site • Going forward, focus is to drive higher capacity utilization including through launch of new products and by acquir
Slide 29: Financial Highlights Proprietary Novel Drugs
Financial Highlights Proprietary Novel Drugs Figures in Rs Cr. Particulars Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 Revenue 0 0 0 4 0 EBITDA (8) (8) (5) (25) (23) 26
Slide 30: Proprietary Novel Drugs Key Highlights & Priorities
Key Highlights & Priorities Proprietary Novel Drugs • Clinical stage precision therapeutics business advancing potent and selective small molecules to address unmet medical needs in oncology and autoimmune diseases • Wholly owned assets; opportunities to explore institutional funding, as well as max
Slide 31: Business Enablers
Business Enablers Jubilant Pharmova Limited 28
Slide 32: Sustainability continues to be an important focus area for us
Sustainability continues to be an important focus area for us Transition towards Renewable Energy Signed Power purchase, Participated in S&P DJSI security subscription and Assessment: shareholder agreement to purchase renewable energy for 90% of electricity demand by - Achieved 94 percentile in the
Slide 33: Annexure
Annexure Jubilant Pharmova Limited
Slide 34: Segment Financial Results Overview | Consolidated
Segment Financial Results Overview | Consolidated Figures in Rs Cr. Total Income (Rs. Cr.) Q3’FY23 Q2’FY24 Q3’FY24 9M’FY23 9M’FY24 FY23 Revenue (A) 1,553 1,680 1,677 4,604 4,944 6,282 a. Radiopharma 613 741 752 1,863 2,184 2,552 Radiopharmaceuticals 213 251 241 657 696 872 Radiopharmacies 400 490 51
Slide 35: For more information
For more information For Investors: Pankaj Dhawan Siddharth Rangnekar Jubilant Pharmova Limited CDR India Ph: +91 120 436 1105 Ph: +91 +91 9769919966 E-mail: Pankaj.dhawan@jubl.com E-mail: siddharth@cdr-india.com For Media: Ryan Marshall Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1062
Jubilant Pharmova — Systematix Group Pharma & Healthcare Conference 2024 on 6ix